UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 222

Sortiert nach

Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials

JNCI : Journal of the National Cancer Institute, 2014-07, Vol.106 (7), p.dju129-dju129

2014

Volltextzugriff (PDF)

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)

JNCI : Journal of the National Cancer Institute, 2014-09, Vol.106 (9), p.dju244-dju244

2014

Volltextzugriff (PDF)

P1.01-12 Trends in the National Cancer Institute (NCI) Sponsored Lung Cancer Clinical Trials Pre and Post NCI’s National Clinical Trials Network (NCTN)

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S359-S360

2019

Volltextzugriff (PDF)

Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer

Journal of clinical oncology, 1996-04, Vol.14 (4), p.1173-1184

1996

Volltextzugriff (PDF)

Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer

Journal of clinical oncology, 1995-08, Vol.13 (8), p.2039-2042

1995

Volltextzugriff (PDF)

Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer

Journal of clinical oncology, 1996-03, Vol.14 (3), p.774-782

1996

Volltextzugriff (PDF)

Pharmacokinetics of Taxol and Doxorubicin Administered Alone and in Combination by Continuous 72-Hour Infusion

JNCI : Journal of the National Cancer Institute, 1994-01, Vol.86 (2), p.143-145

1994

Volltextzugriff (PDF)

Implementation of Timeline Reforms Speeds Initiation of National Cancer Institute―Sponsored Trials

JNCI : Journal of the National Cancer Institute, 2013-07, Vol.105 (13), p.954-959

2013

Volltextzugriff (PDF)

Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients

Journal of clinical oncology, 1996-01, Vol.14 (1), p.95-102

1996

Volltextzugriff (PDF)

A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients

Annals of oncology, 1994-10, Vol.5 (8), p.709-716

1994

Volltextzugriff (PDF)

Tamoxifen and fenretinide in women with metastatic breast cancer

Breast cancer research and treatment, 1999-10, Vol.57 (3), p.277-283

1999

Volltextzugriff (PDF)

Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer

Human gene therapy, 1994-07, Vol.5 (7), p.891-911

1994

Volltextzugriff (PDF)

The Cancer Therapy Evaluation Program’s (CTEP) implementation of the Operational Efficiency Working Group (OEWG) recommendations

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6113-6113

2011

Volltextzugriff (PDF)

A comparison of patient-reported outcomes (PROs) in National Cancer Institute-sponsored cancer treatment trials conducted during two time periods: 1999–2003 and 2003–2008

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.6618-6618

2009

Volltextzugriff (PDF)

Validation study of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS274-TPS274

2010

Volltextzugriff (PDF)

Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor

Journal of clinical oncology, 1993-09, Vol.11 (9), p.1795-1803

1993

Volltextzugriff (PDF)

Early success in narrowing age, gender, and racial disparities in clinical trial accrual: Targeted screening efforts through the National Cancer Institute Community Cancer Centers Program (NCCCP)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6110-6110

2011

Volltextzugriff (PDF)

Tracking clinical trial accrual strategies and barriers via a Web-based screening tool

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.6586-6586

2009

Volltextzugriff (PDF)

Oncology nurse and physician attitudes toward aggressive cancer treatment

Cancer nursing, 1993-04, Vol.16 (2), p.107-112

1993

Volltextzugriff (PDF)

Phase II study of fazarabine (NSC 281272) in patients with metastatic colon cancer

Investigational new drugs, 1993-02, Vol.11 (1), p.71-74

1993

Volltextzugriff (PDF)

Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor

Cancer research (Chicago, Ill.), 1993-06, Vol.53 (11), p.2587-2590

1993

Volltextzugriff (PDF)

Expanding participation to non-group members in phase III cooperative group treatment trials

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.6533-6533

2007

Volltextzugriff (PDF)

Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer

Clinical cancer research, 1995, Vol.1 (1), p.129-136

1995

Volltextzugriff (PDF)

Nursing management of the patient receiving Taxol therapy

Journal of the National Cancer Institute. Monographs, 1993 (15), p.149

1993

Volltextzugriff (PDF)

Therapy of patients with metastatic breast cancer with 5-fluorouracil, leucovorin and carboplatin

Anti-cancer drugs, 1992-10, Vol.3 (5), p.463

1992

Volltextzugriff (PDF)

1 – 25 von 222

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(200)
Mit Volltextzugriff
(195)

Publikationsform

Sprache

Englisch
(222)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Humans
(133)
Science & Technology
(119)
Life Sciences & Biomedicine
(118)
Biological And Medical Sciences
(75)
Medical Sciences
(75)
Female
(73)
Adult
(71)
Psychiatry
(64)
Male
(58)
Middle Aged
(47)
Oncology
(45)
Psychology. Psychoanalysis. Psychiatry
(42)
Pharmacology. Drug Treatments
(41)
Bipolar Disorder - Drug Therapy
(39)
Aged
(33)
Neurosciences & Neurology
(31)
Psychopathology. Psychiatry
(29)
United States
(28)
Mood Disorders
(25)
National Cancer Institute
(25)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)

P1.01-12 Trends in the National Cancer Institute (NCI) Sponsored Lung Cancer Clinical Trials Pre and Post NCI’s National Clinical Trials Network (NCTN)

Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer

Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer

Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer

Pharmacokinetics of Taxol and Doxorubicin Administered Alone and in Combination by Continuous 72-Hour Infusion

Implementation of Timeline Reforms Speeds Initiation of National Cancer Institute―Sponsored Trials

Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients

A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients

Tamoxifen and fenretinide in women with metastatic breast cancer

Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer

The Cancer Therapy Evaluation Program’s (CTEP) implementation of the Operational Efficiency Working Group (OEWG) recommendations

A comparison of patient-reported outcomes (PROs) in National Cancer Institute-sponsored cancer treatment trials conducted during two time periods: 1999–2003 and 2003–2008

Validation study of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)

Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor

Early success in narrowing age, gender, and racial disparities in clinical trial accrual: Targeted screening efforts through the National Cancer Institute Community Cancer Centers Program (NCCCP)

Tracking clinical trial accrual strategies and barriers via a Web-based screening tool

Oncology nurse and physician attitudes toward aggressive cancer treatment

Phase II study of fazarabine (NSC 281272) in patients with metastatic colon cancer

Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor

Expanding participation to non-group members in phase III cooperative group treatment trials

Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer

Nursing management of the patient receiving Taxol therapy

Therapy of patients with metastatic breast cancer with 5-fluorouracil, leucovorin and carboplatin

Suchergebnisse filtern